论文部分内容阅读
新辅助化疗已经成为乳腺癌综合治疗的重要组成部分,临床实践中迫切需要一种能准确评价新辅助化疗的方法为临床制订最佳的治疗方案提供依据。近年来,定量磁共振成像技术在早期评价乳腺癌新辅助化疗疗效方面显示出独特的优势。它通过监测肿瘤内一些可量化的参数,可在细胞分子功能水平对经新辅助化疗后肿瘤发生的变化进行客观定量的分析,在肿瘤形态发生改变之前评估乳腺癌新辅助化疗的疗效。因此,定量磁共振成像技术有望成为早期评价乳腺癌新辅助化疗疗效的有效手段。
Neoadjuvant chemotherapy has become an important part of comprehensive treatment of breast cancer. In clinical practice, there is an urgent need for a method that can accurately evaluate neoadjuvant chemotherapy to provide the basis for the best clinical treatment plan. In recent years, quantitative magnetic resonance imaging in the early assessment of the efficacy of neoadjuvant breast cancer showed a unique advantage. By monitoring some of the quantifiable parameters in the tumor, it can objectively and quantitatively analyze the changes of tumorigenesis after neoadjuvant chemotherapy at the cellular molecular level and evaluate the efficacy of neoadjuvant chemotherapy before the change of tumor morphology. Therefore, quantitative magnetic resonance imaging is expected to be an effective means to evaluate the efficacy of neoadjuvant chemotherapy in breast cancer in the early stage.